Inicio > Oftalmología > Tratamiento de la ambliopía con Levodopa oral a dosis mínima añadido a la terapia con oclusión, en pacientes entre 8 y 18 años > Página 6

Tratamiento de la ambliopía con Levodopa oral a dosis mínima añadido a la terapia con oclusión, en pacientes entre 8 y 18 años

2. Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology 1993; 100: 323-7.

3. Pritchard C. Why won’t you treat my 10 year old’s lazy eye? American Orthoptic Journal 1990; 40: 15-18.

4. Rahi JS, Logan S, Borja MC, et al.: Prediction of improved vision in the amblyopic eye after visual loss in the non-amblyopic eye. Lancet 2002; 360:621–622.

5. Mohan K; Saroha V; Sharma A. Successful Occlusion Therapy for Amblyopia in 11- to 15-Year-Old Children. J Pediatr Ophthalmol Strabismus 2004; 41:89–95. (Abstract)

6. Simmonds K. Amblyopia Characterization, treatment and prophylaxis. Surv Ophthalmol 2005; 50(2): 123-166.

7. Chua B. MitchelL P. Consequences of amblyopia on education, occupation, and long term vision loss. Br J Ophthalmol 2004; 88(9):1119-21.

8. Pandey PK, Chaudhuri Z y Kumar M.et al. Effect of levodopa and carbidopa in human amblyopia, J Pediatr Ophthalmol Strabismus 2002; 39 (2): 81–89.

9. Leguire LE, Walson PD, Rogers GL, Bremer DL, McGregor ML Levodopa/carbidopa treatment for amblyopia in older children. J Pediatr ophthalmol Strabismus 1995; 32 (3): 143-51.

10. Bhartiya P; Sharma P; Biswas NR; Tandon R; Khokhar SK. Levodopa-carbidopa with occlusion in older children with amblyopia. 2002 J AAPOS; 6:368-72.

11. Leguire LE, Komaromy KL, Nairus TM, Rogers GL. Long-Term follow-up of L-dopa treatment in children with amblyopia. J Pediatr Ophthalmol Strabismus 2002; 39 (6):326-30.

12. Basmak H, Yildirim N, Erdnic O, Yurdakul S y Ozdemir G. Der effect der levodopatherapie auf das visuell evozierte Potential und die Sehscharfe in der amblyopie. Ophthalmologica 1999; 213: 110-113.

13. Alagaze A, Leguire LE, Roberts C, Ibinson JW, Lewis JR, Rogers G. The effects of L-dopa on the functional magnetic resonance imaging response of patients with amblyopia: a pilot study. J AAPOS 2005 Jun; 9(3):216-23.

14. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of Amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005; 123:437-447.

15. Yang X , Luo D. Eficacia y tolerancia de la levodopa para el tratamiento de la ambliopía: una revisión sistemática y meta-análisis. European journal of ophthalmology año – 2012

16. – Hertle RW et al. Stability of visual acuity improvement following discontinuation of amblyopia treatment in children aged 7 to 12 years. Archives of Ophthalmology 2007; 125(5): 655-9.

17.- Carrión Ojeda Carlos et al. Ametropía y ambliopía en escolares de 42 escuelas del programa «Escuelas Saludables» en la DISA II, Lima. Perú, 2007-2008. Acta méd. Peruana [online]. 2009, vol.26, n.1, pp. 17-21. ISSN 1728-5917.

18. – Tejedor J, Ogallar C. Comparative efficacy of penalization methods in moderate to mild amblyopia. American Journal of Ophthalmology 2008; 145(3): 562-9

19. – The Baltimore Pediatric Eye Disease Study, Methods, and Results. Prevalence of Decreased Visual Acuity among Preschool-Aged Children in an American Urban Population. Ophthalmology, 2008; 115: 1786-1795.

20. – Quing Lu et al. A Population-based Study of Visual Impairment Among pre-school Children in Beijing: The Beijing Study of visual impairment in Children. Am J Ophthalmol, 2009; 147: 1075-81.

21.-Friedman et al. Lack of concordance between fixation preference and HOTV Optotype visual acuity in preschool children. The Baltimore Pediatric Eye Disease Study. Ophthalmology.2008; 115: 1796-99.

22.- Holmes JM, Beck RW, et al. s.l The amblyopia treatment study visual acuity testing protocol.. : Arch Ophthalmol. 2001;119: 1345-53.

23.- Estrabismo y Oftalmología Pediátrica. Consejo Argentino de Oftalmología Pediátrica Universidad Católica del Salta, Tratamiento de ambliopía con levodopa. Cap 18. Pg. 335 – 2004

24. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol 2005;123:437-447.

25.Simmonds K. Amblyopia characterization, treatment and prophylaxis. Surv Ophthalmol 2005; 50(2): 123-166.

26.- Epelbaum M, Milleret C, Buisseret P, Dufier JL. The sensitive period for strabismic amblyopia in humans. Ophthalmology 1993; 100: 323-7.

27.- Mohammad A Rashad, Pharmacological enhancement of treatment for amblyopia. Clinical Ophthalmology 2012:6 409–416.

28.- Rahi J, Logan S, Timms C, Russell-Eggitt I, Taylor DSI. Incidence andcauses of new visual loss affecting the non amblyopic eye of individualswith unilateral amblyopia in United Kingdom. Invest Ophthalmol Vis Sci. 2000;41:297.

29.- Grosvenor, Theodore (2007). Primary care Optometry. St. Louis, Missouri: ELSEVIER. pp. 174–175. ISBN 9780750675758.

30.- http://www.nvri.org.au/pages/first-research-starts-in-1974.html

31.- Bailey IL, Lovie JE. I (1976.) New design principles for visual acuity letter charts. Am J Optom Physiol Opt. Nov;53(11):740-5.

32.- Carlson, Kurts, Nancy, Daniel (2004). Clinical Procedures of Ocular Examination. U.S.A: McGraw HIll. p. 10. ISBN 0-07-137078-1.

33.- Virgili G, Acosta R, Grover LL, Bentley SA, Giacomelli G (2013). «Reading aids for adults with low vision». Cochrane Database Syst Rev 10: CD003303. doi:10.1002/14651858.CD003303.pub3. PMID 24154864.

34.- Mohammad A Rashad Pharmacological enhancement of treatment for amblyopia, Clinical Ophthalmology 2012:6